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Abstract
The pattern of viral diversification in newly infected individuals provides information about the host environment and
immune responses typically experienced by the newly transmitted virus. For example, sites that tend to evolve rapidly
across multiple early-infection patients could be involved in enabling escape from common early immune responses, could
represent adaptation for rapid growth in a newly infected host, or could represent reversion from less fit forms of the virus
that were selected for immune escape in previous hosts. Here we investigated the diversification of HIV-1 env coding
sequences in 81 very early B subtype infections previously shown to have resulted from transmission or expansion of single
viruses (n=78) or two closely related viruses (n=3). In these cases, the sequence of the infecting virus can be estimated
accurately, enabling inference of both the direction of substitutions as well as distinction between insertion and deletion
events. By integrating information across multiple acutely infected hosts, we find evidence of adaptive evolution of HIV-1
env and identify a subset of codon sites that diversified more rapidly than can be explained by a model of neutral evolution.
Of 24 such rapidly diversifying sites, 14 were either i) clustered and embedded in CTL epitopes that were verified
experimentally or predicted based on the individual’s HLA or ii) in a nucleotide context indicative of APOBEC-mediated G-to-
A substitutions, despite having excluded heavily hypermutated sequences prior to the analysis. In several cases, a rapidly
evolving site was embedded both in an APOBEC motif and in a CTL epitope, suggesting that APOBEC may facilitate early
immune escape. Ten rapidly diversifying sites could not be explained by CTL escape or APOBEC hypermutation, including
the most frequently mutated site, in the fusion peptide of gp41. We also examined the distribution, extent, and sequence
context of insertions and deletions, and we provide evidence that the length variation seen in hypervariable loop regions of
the envelope glycoprotein is a consequence of selection and not of mutational hotspots. Our results provide a detailed view
of the process of diversification of HIV-1 following transmission, highlighting the role of CTL escape and hypermutation in
shaping viral evolution during the establishment of new infections.
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Introduction
Adaptation of HIV-1 to new hosts, in particular to the initial
immune response, is likely to influence the establishment and
progressionofHIVinfection.Mutationsthatenableescapefromthe
host’s immune responses will come under selective pressure, in an
order that reflects the timing of the immune responses, underlying
mutational rates, and the relative fitness costs of mutations. In
addition, escape mutations that occurred in the infecting host,
particularly those resulting in a reduction of viral fitness [1], will
come under selective pressure to revert to wild-type in the newly
infected individual [2]. If transmission itself is a selective process,
such that, for example, viral variants that are adapted to replication
in mucosal cell types are selectively transmitted, the virus may
experience selection to acquire forms that are adapted to replication
in other host tissues. Since the viral envelope glycoprotein (Env)
plays a vital role in transmission, is an early target of immune
responses, and a key determinant of target cell tropism, the early
evolution of the HIV-1 envelope gene is of particular interest.
Env is a trimeric glycoprotein composed of three gp120 and
gp41 heterodimers that are exposed on the viral surface and are
anchored on the viral particle by the transmembrane domains of
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gp120 to the CD4 receptor, followed by CCR5 or CXCR4
coreceptor binding [3], which then induces conformational
changes in gp120 that trigger the activation of gp41 [4–6].
Activated gp41 leads to fusion with the target cell membranes, and
virus entry [5,7]. The development of vaccines capable of eliciting
antibodies against Env that can block viral entry is complicated by
the vast sequence variability between viruses, escape variants
arising through the high mutation and recombination rates
coupled with immune selection, as well as by the large number
of N-linked glycans in gp120 that provide the virus with a
protective coat [5,8]. In addition, gp120 consists of five highly
variable (V1–V5) regions interspersed among more conserved
(C1–C5) regions [9]; of these, V1, V2, V4 and V5 are notable for
rapid shifts in the length, number and localization of glycosylation
sites [10,11]. The variable loops shield more conserved receptor
binding regions [12], and only when the CD4-gp120 binding takes
place, do structural changes expose previously masked epitopes
and surfaces [13,14].
The transmission of HIV is associated with a severe population
bottleneck, such that, in most cases, new infections result from
transmission or expansion of a single virus [15]. We have recently
shown that the sequence of the virus that is transmitted can be
identified accurately through direct sequencing of the uncloned
DNA amplicons derived from single genome amplification (SGA)
of plasma viral RNA sampled during acute and early infection
[15,16]. For that study, each of 102 HIV-1 subtype B primary
infections was classified into one of six clinical stages according to
patterns of laboratory assay reactivity defined by Fiebig et al. [17].
Out of 102 patients, there was evidence of infection by or rapid
outgrowth of a single virus (or in three cases possibly two closely
related viruses) for 81 of these individuals [15]. In the present study
we have carried out a detailed analysis of the early evolution and
divergence of the virus from the ancestral infecting strain in these
81 homogeneous infections. We restricted our study to the
homogeneous infections because in these patients the observed
sequence diversity is expected to be due mainly, or entirely (in the
case of transmission of a single viral variant), to mutations that
have occurred following transmission. The data analyzed in this
study consisted of sets of between 10 and 67 sequences per patient,
generated previously [15] using SGA from single time-points in
acute or early infection.
Phylogenetic trees of the sequences from individual patients had
short branch lengths and few internal branches, reflecting the
short time since transmission and rapid expansion in the new host.
It was not possible to apply standard phylogenetic models of
evolution to these data to assess whether diversification of the virus
following transmission is primarily a stochastic process, or driven
by evolutionary selection pressure, because sequences from
individual patients provide too little information to allow statistical
discrimination between alternative evolutionary models. However,
by considering all patients simultaneously, it was possible to
determine whether similar patterns of sequence diversification
were repeated either in multiple patients or within the same
patient. Shared patterns of rapid diversification at the same codons
in early infection can reveal sites that are typically involved in viral
adaptation to the new host at the earliest stage of infection. In
cases where these sites are associated with specific host immune
responses, they shed light on the nature, extent, and timing of the
immune responses that most frequently exert selective pressure on
the transmitted virus during acute and early infection. However,
there is also the possibility that shared mutations across multiple
patients may be the result of deviation from the expected mutation
rates, so that particular sites with high mutation rates, for example
resulting from APOBEC-mediated substitutions, might be mutat-
ed in an unexpectedly high proportion of patients.
Using HyPhy [18], an interpreted computer programming
environment for fitting evolutionary models, we have developed a
method that can identify sites in env that tend to diversify most
rapidly across recently infected patients, and explored the reasons
for rapid diversification at these sites. The sequence of the
transmitted founder virus at or near the time of transmission,
which had been inferred previously [15], enabled us to determine
the direction of single base mutations and to distinguish between
insertions and deletions. A relative reduction in the length of the
variable loops of env has previously been reported at transmission
compared to chronic infection [19,20] and this is thought to be an
important characteristic of acute subtype A and C infections [21].
Indels may also affect antibody recognition [22], and, in
consequence, may be under selective pressure. We have also
carried out a detailed analysis of the length distribution and
locations of insertions and deletions in early infection and
investigated the existence of indel hotspots in the envelope gene.
In this study we found that i) there is evidence of positive selection
in early HIV-1 infection, which appears to be driven in many cases
by escape from early cytotoxic T lymphocyte (CTL) responses; ii)
in several cases CTL escape occurred via mutations in the
APOBEC sequence context, suggesting a role for APOBEC in
determining the pathway of immune escape; and iii) frameshifting
insertions and deletions are evenly spread throughout env but are
preferentially fixed in the variable regions. These results provide
the most detailed view yet of the process of diversification of the
homogeneous viral population following transmission.
Results
Model-based inference of selection in early infection
We fitted models of codon sequence evolution to 2,207 env
coding sequences from early stages of HIV-1 infection as described
in the Methods section. In order to accumulate evidence of
selection from multiple patients the models were implemented
such that at a given site the value of v (the ratio of nonsynonymous
Author Summary
HIV is a rapidly evolving virus, displaying enormous
genetic diversity between and even within infected
individuals, with implications for vaccine design and drug
treatment. Yet, recent research has shown that most new
infections result from transmission of a single virus
resulting in a homogeneous viral population in early
infection. The process of diversification from the transmit-
ted virus provides information about the selection
pressures experienced by the virus during the establish-
ment of a new infection. In this paper, we studied early
diversification of the envelope gene in a cohort of 81
subjects acutely infected with HIV-1 subtype B and found
evidence of adaptive evolution, with a proportion of sites
that tended to diversify more rapidly than expected under
a model of neutral evolution. Several of these rapidly
diversifying sites facilitate escape from early cytotoxic
immune responses. Interestingly, hypermutation of the
virus, brought about by host proteins as a strategy to
restrict infection, appeared to be associated with early
immune escape. In addition to single base substitutions,
insertions and deletions are an important aspect of HIV
evolution. We show that insertion and deletion mutations
occur evenly across the gene, but are preferentially fixed in
the variable loop regions.
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in all patients. This enabled us to use standard model comparison
techniques to investigate whether there was evidence that the
mean value of v across patients was significantly greater than one
at a subset of sites in the alignment (see Methods). We found that,
as expected, the majority of codon sites evolve under the influence
of purifying selection (with v,1) in early infection and the mean
value of v across all sites in all patients was 0.67. Three
overlapping groups of patients were considered, consisting of
individuals in the earliest clinical stages (Fiebig stages I and II),
earliest through intermediate stages (Fiebig stages I through III)
and all patients in early infection (Fiebig stages I through V). For
the data from Fiebig stages I and II the model allowing a subset of
sites to evolve under positive selection did not provide a
significantly better fit to the data than the model in which positive
selection was not permitted (p=0.52; Table 1). For the other two
datasets, however, the selection model (M2a) provided a
significantly better fit to the data than the model in which
selection was excluded (M1a). M1a was rejected against M2a with
p-values 0.006 and 0.0001 in the case of the datasets from Fiebig
stages I–III and stages I–V, respectively (Table 1).
For this analysis all individual sequences with evidence of
APOBEC-mediated hypermutation were removed using Hyper-
mut 2.0 (www.hiv.lanl.gov). For fifteen of the patients the env
sequences showed an overall elevated rate of GRA mutations in a
sequence context associated with APOBEC hypermutation (using
the methodology described in the supplementary data of [15]; see
Figure S1) even though no individual sequences showed evidence
of hypermutation Hotspots of mutation could create false positive
signatures of positive selection, particularly if the same hotspots are
repeated across multiple patients, as we would expect for mutation
hotspots resulting from APOBEC hypermutation. To limit the
impact of hypermutation on our results, these patients were
removed from the dataset, leaving 66 subjects. Interestingly, even
with these precautions, we found that sites that were placed in the
set of sites with v.1 (positive selection site class) are enriched for
the APOBEC-motif (see Table 2). Because of the potential
biological relevance of these mutations we performed a second
analysis including all 81 homogeneous patients, bearing in mind
the caveat that the model may be affected by the higher rate of
GRA mutation in the APOBEC context and that some of the sites
identified from this dataset may reflect mutational hotspots rather
than selection acting on the amino acid sequence.
Analysis of rapidly evolving sites
We found 24 sites in env with posterior probability .0.5 of
belonging to the positive selection site class based on the 66
subjects discussed above (Table 2). Thirteen of these occurred in
gp120 and eleven in gp41 (Figure 1). The three-dimensional
structure context of the selected sites in gp120 is shown in
Figure 2A. There is a cluster of sites in the C3 region of gp120
(Table 2) that are in the positive selection class. In general, sites
evolving under positive selection appear to be at least partially
solvent exposed (Figure 2A). Six additional sites were identified by
including all 81 subjects in the analysis (Table 2, and Figure 2B); 4
were in gp120. For all of the sites identified we considered the
sequence alignment carefully to assess the possibility that the
evidence of positive selection could be resulting, for example, from
APOBEC-mediated mutations or alignment errors associated with
indel hotspots (Table S1, provides a detailed list of the observed
mutations and their sequence context). For one site (at position
509 on the HXB2 sequence), alignment error introduced by an
indel hotspot provides a better explanation of the data than
selection. This site occurs at the beginning of a long sequence of
Adenines that could serve as an indel hotspot [23] and mutations
at this site could, in several cases, be more parsimoniously
explained as indels. For 7 of the 24 identified sites (indicated in
Table 2) some or all of the mutations involve GRA in the
APOBEC3G or APOBEC3F hypermutation motif (the motif is
GRD, where R is the IUPAC code for G or A, and D for G, A, or
T). A baseline of 12.3% of the bases in the patients’ transmitted
sequences corresponded to a G embedded in an APOBEC3 motif,
while 26.8% (25/93) of the distinct mutations found in the 24 sites
identified as evolving under positive selection involved a G in an
APOBEC3 motif. When all 81 patients were included, 12.3% of
the bases in transmitted sequences were G’s in an APOBEC3
motif, while 28.6% (32/112) of the observed changes in selected
sites involved a G in an APOBEC3 motif. In contrast, G’s not
embedded in an APOBEC motif were not enriched among sites
under positive selection relative to the transmitted virus. Indeed,
the proportion of G’s embedded in an APOBEC3 motif was
significantly higher for the selected sites than for the remainder of
the virus in both the 66 patient subset (Fisher’s exact test
p=0.004), and the full 81 patient (p=0.0002) data set. This
suggests that some of the sites are identified as belonging to the
positive selection class because of the elevated APOBEC3
mediated mutation. Because the waiting time for GRA mutations
in the APOBEC3 context may be shorter than for other
mutations, it is possible that selection acting on these mutations
may be a hallmark of early immune escape.
There were 10 positively selected sites that were located in 5
potential CTL epitopes. An additional site (position 965 in the
alignment) that was detected as an enriched change in late
infection (Figure 3F, also see below) was embedded in a 6
th
potential epitope. These selected sites were investigated as
potential CTL epitopes because each was embedded in a localized
region with multiple mutations in one of the study subjects
(Figure 3), and some of the variants were repeated multiple times
within the subject (Figure 3), two features providing corroborative
evidence for ongoing positive selection for immune escape. In each
of these six cases, the cross-sectional sample appeared to capture a
moment of transition in the viral population, with the virus
exploring different escape options. In each of these cases, patient
HLA data were available, and the clusters of mutations were found
to occur either within a known CTL epitope from the literature, or
within anchor motifs appropriate for the HLA type of the infected
Table 1. Parameter estimates for the neutral and selection model applied to env sequences from different Fiebig stage datasets.
Fiebig Stage dN/dS: Neutral Model (M1a) dN/dS: Selection Model (M2a) 2 * Delta Log Likelihood P-value (M1a vs M2a)
I–II 0.6912 0.6995 1.2833 0.5264
I–III 0.6687 0.7016 10.0741 0.0065
I–V 0.6307 0.7130 18.3186 0.0001
doi:10.1371/journal.ppat.1000414.t001
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hypermutation, as well as from the complete dataset including the hypermutated sequences (the latter sites are indicated with +).
HXB2 Data Location
Posterior
Probability
p-value/
q-value
Number of
subjects with
variation
APOBEC3 in
subject’s
mutations
Timing
(Fiebig
Stage)
Number of subjects with a mutational
pattern out of all 81 subjects
CTL
testing
62 79 gp120 C1 0.765 - 5 4 of 5 I–V 2 D to N, 1 D to Y, 2 E to K Yes
64 81 gp120 C1 0.505 - 2 No I–V 2 E to G Yes
66 83 gp120 C1 0.979 - 4 No I–V 4 H to Y Yes
66 , 83 gp120 C1 - 0.006/0.04 4 No IV–VI 4T oY Yes
66 , 83 gp120 C1 - 0.006/0.05 4 No IV–VI 4 Away from H Yes
175 226 gp120 V2 0.983 - 7 No I–V 3 L to P, 3 L to F, 1 N to S No
176 227 gp120 V2 0.655 - 2 No I–V 1 F to S, 1 F to V No
232 306 gp120 C2 0.853 - 4 No I–V 1 K to E, 1 K to R, 1 T to A, 1 T to M No
242 316 gp120 C2 0.652 - 3 No I–V 2 V to I, 1 V to L No
274 349 gp120 C2 0.722 - 3 No I–V 1 S to T, 1 S to F, 1 S to P No
322 + 396 gp120 V3 0.51 - 4 2 of 4 I–V 2 E to K, 1 E to G, 1D to N No
337 412* gp120 C3 0.932 - 5 2 of 5 I–V 1 K to E, 1 K to R, 1 E to K, 1 D to N, 1 D to A No
344 + 419 gp120 C3 0.588 - 3 No I–V 1 K to M,1Qt oL ,1Rt oG N o
347 + 422 gp120 C3 0.91 - 5 4 of 5 I–V 2 R to K, 1 K to R, 1 G to R, 1 G to E No
354 431 gp120 C3 0.895 - 3 2 of 3 I–V 1 E to K, 1 G to E, 1 K to R/T Yes
360 439 gp120 C3 0.897 - 3 No I–V 1 V to G, 1 V to A, 1V to G/A Yes
372 , 454* gp120 C3 - 0.070/0.14 1N o I – I I * 1 Away from A No
381 , 463 gp120 C3 - 0.042/0.19 4 4 of 4 III–VI 4 To K No
381 , 463 gp120 C3 - 0.042/0.09 4 4 of 4 III–VI 4 Away from E No
460 566 gp120 C4 0.87 - 2 No I–V 1 N to K, 1 D to N/K/T Yes
460 , 566 gp120 C4 - 0.006/0.08 2 No IV–VI 2 Away from N Yes
482 + 601 gp120 C5 0.669 - 5 5 of 5 I–V 5 E to K No
509 634 gp120 C5 0.904 - 7 7 of 7** I–V 7 E to K No
513 638 gp41 0.728 - 2 No I–V 1 V to S, 1 V to G No
518 646 gp41 0.999 - 9 No I–V 2 M to I, 7 M to V No
587 719 gp41 0.77 - 2 No I–V 2 L to I No
588 720 gp41 0.546 - 3 2 of 3 I–V 2 R to K, 1 K to R No
612 744 gp41 0.841 - 2 No I–V 1 I to T/S/N,1Tt oI Y e s
632 , 768 gp41 - 0.042/0.10 4 4 of 4 III–VI 4 To K No
632 , 768 gp41 - 0.037/0.17 4 4 of 4 III–VI 4 Away from E No
648 , 786 gp41 - 0.080/0.18 3 3 of 3 III–VI 3 To K No
651 789 gp41 0.598 - 3 No I–V 2 N to S,1St oG N o
696 834 gp41 0.635 - 7 6 of 7 I–V 6 R to K,1Rt oS N o
700 838* gp41 0.535 - 3 No I–V 1 A to V, 1 A to T,1 T to S No
702 + 840 gp41 0.533 - 3 No I–V 2 L to F, 1 L to P No
703 + 841 gp41 0.541 - 3 No I–V 1 S to A, 1 S to F, 1 S to P No
817 , 965 gp41 - 0.002/0.29 2 No V–VI 2T oT Yes
817 , 965 gp41 - 0.003/0.048 2 No V–VI 2 Away from A Yes
831 979 gp41 0.664 - 2 2 of 2 I–V 2 E to K*** Yes
831 , 979 gp41 - 0.029/0.082 2 2 of 2 V–VI 2T oK Yes
833 981 gp41 0.993 - 2 No I–V 1 V to A, 1 V to A/G Yes
833 , 981 gp41 - 0.010/0.15 2 No V–VI 2T oV Yes
841 989 gp41 0.772 - 4 No I–V 1 L to H or gap, 1 L to P, 1 L to F, 1 I to T Yes
Sites identified using the maximum likelihood phylogeny-based method are indicated with , . The location, timing, and mutational patterns observed are provided as
well as an indication of whether CTL testing was carried out or not.
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summarized in Table 3, identified using the tool ELF http://www.
hiv.lanl.gov/content/sequence/ELF/epitope_analyzer.html). As
this was a cross-sectional study, the sequences from which we
infer selective pressure are from the moment of transition, thus
only direct experiments can determine which of the variants
represent the susceptible form.
To determine if there indeed was a T-cell response to these
putative epitopes, 18 amino acid long peptides representing the
most common and second most common form of the regional
variants encompassing the variable sites, as well as the predicted
epitopes shown in Figure 3, were synthesized and tested using
either ELISpot or ICS (see Methods). For example, three sites (79,
81 and 83 in the alignment), showing evidence of adaptive
evolution (Table 2) were mutated in patient MEMI. These sites
were embedded within a previously described B*5801 epitope, and
MEMI carried HLA B*5801 (Figure 3A). Upon testing, MEMI in
fact did make a T-cell response to the most common form of the
B*5801 epitope (KAHDPEVHNVW) and a diminished response
to the variant KAHDPEVYNVW (Table 3). We were able to
detect a T-cell response to 4 of the 6 proposed epitopes we tested
(Table 3). The lack of the response to the other 2 proposed
epitopes could imply an alternative cause for the selection at this
sites (e.g. antibody escape or reversion). However, it is also possible
that all of the observed forms of the peptide are escape variants,
and that the susceptible form has decreased in frequency to the
extent that it does not appear in the sample and was therefore not
tested. Further possible explanations include a transient T-cell
response driving the escape that was already beginning to subside
due to immune escape and reduced stimulation, or limited sample
viability (this was a retrospective study, and the condition of
several of the samples was not ideal).
Interestingly, 3 of the 4 validated T-cell escape forms included a
GRA mutation embedded in APOBEC3G or 3F motif, a further
indication that an APOBEC-mediated enhanced mutation rate
may facilitate early CTL immune escape in some cases (Table 3).
Clusters of mutations that co-occur in a patient may represent an
alternate way in which immune escape can be inferred and is
consistent with previously observed patterns of escape from an
immune response early in infection [24]. Again, patient MEMI
provides an example, with at least three independent nonsynon-
ymous substitutions at site 566, which was embedded in a
proposed but not validated epitope for one of the HLA alleles of
this patient (B*0801). Collectively the results suggest that there is
strong evidence for selection preferentially occurring within CTL
epitope regions relatively early in infection – all potential CTL
escape variants were found among Fiebig stage V cases in this
study (Table 3).
The 12 other sites that were identified cannot be explained by
APOBEC mediation and do not occur within mutation clusters
and were therefore not investigated as possible CTL epitopes. Two
sites (412 and 838 in the alignment) are identified largely because
of mutations in patients Z31 and TT31P, where infection may
have resulted from multiple closely related strains of the virus,
rather than a single viral strain [15]. For all but two of the
remaining sites, the observed mutation occurred on a single
terminal branch of the within-patient phylogenetic tree and
mutations were consequently observed only once per patient.
These sites were identified as under positive selection because the
site was mutated in multiple patients. Thus, unlike the substitution
patterns in the putative CTL epitopes described above, there was
no evidence at this stage of infection that these mutations were
spreading in the intra-patient viral populations. As a result, these
sites may be mutational hotspots, albeit hotspots that cannot be
explained by known mechanisms of hypermutation in HIV-1.
Note that two patients may share a mutation at a given site by
chance with a probability of 0.12 (calculation described in the
Methods section), but the probability falls off rapidly as more
Key for Table 2
HXB2: Coordinates listed according to HXB2 numbering (http://www.hiv.lanl.gov/content/sequence/LOCATE/locate.html)
Data: Coordinate listed according to the protein alignment of all 81 acutely infected subjects.
Location: Region in Envelope.
Posterior Probability: Sites identified in HyPhy with a posterior probability.0.5 are included in this table.
P-value/q-value: The p and q values from the Phylogenetic analysis for a specific mutational pattern being associated with an earlier or later Fiebig stage.
Number of subjects with variation: Out of the 81 subjects, the number that had any variation in this site.
APOBEC3 in subject’s mutations: The number of subjects among those that vary in a given position that have a G to A change in the context of an APOBEC3 motif.
Timing: The selection results were obtained using all samples in Fiebig stages I–V.
For the phylogenetic method a change at the site was enriched in the range of Fiebig stages shown.
Number of subjects with a mutational pattern: This summarizes all individuals with changes found in this position in the data. Italics means a change was found
more than once in at least one person with the pattern.
Posterior probabilities: The number of individuals that have a change from the most common amino acid to another. If there was more than 1 change in any of the
individuals, it is noted in italics.
Example 1: Site 651: 2 N to S, 1 S to G means: Two people had N as the most common amino acid, but S was present. PRB931 had 17 N and 2 S, PRB956 had 25 N
and 1 S. Because there was more than one S in one of them, it is in italics. One person, 700010077, in noted as S to G, and had 51 S and 1 G.
Example 2: Site 518: 2 M to I, 7 M to V means: Nine people had M as the most common amino acid, and each of the nine had a single variant among their sequences,
and it was I in 2 of them, or V in nine of them. For example, subject 1012 had 42 sequences, with 41 M and 1 V.
Phylogenetic method: The within-subject change that was observed to be enriched either early or late Fiebig stages.
Example: Site 460: 2 Away from N means: In the subjects that had changes in this position, the ancestral state of the founding virus (the transmitted virus) was most
likely to be N, and in both cases at least one change away from N was observed. Because it is italics, at least one of the two carried more than one mutation from N in
this position.
CTL testing: If a variant was found multiple times in a patient or embedded in the context of additional proximal changes, peptides spanning the region were
generated and T-cell assays were perform (see Table 3).
*In Keele et al., we noted patients bearing these changes might have been infected with more than one closely related form. Alternatively, early selection or
maintenance of a very early mutational event might be giving rise to the pattern.
**This site was difficult to align in a few patients due to a frameshifting insertion of an A in a string of As in the primary sequences, thus some of 7 noted E to K changes
were actually due to a frameshifting indel.
***In an additional subject there was an ambiguous base call in this position.
doi:10.1371/journal.ppat.1000414.t002
Table 2. cont.
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probability of three patients sharing a mutation at the same site is
0.03, and for four patients this drops to 0.004. Even then, seeing,
for example, seven changes within a codon (four at one position
and three at another) once in a sequence of length 2568 (the median
sequence length) is quite likely (p=0.45). Using this approach,
only at one site in the alignment (646, which is codon 518 in the
HXB2 strain) do we find a significantly greater number of patients
Figure 1. Posterior probabilities of belonging to the selection class (v.1) for all sites in gp160. The dashed line indicates the 0.5
posterior probability, which we used as a threshold to assign sites to the selection site class. Flat parts of the graph correspond to sequence regions
that were masked either because they were poorly aligned or coding in more than one frame.
doi:10.1371/journal.ppat.1000414.g001
Figure 2. Three-dimensional structure context of the selected sites identified in gp120. (A) 13 sites from the dataset excluding sequences
with evidence of APOBEC-mediated hypermutation, and (B) 4 additional sites identified analyzing the complete dataset. The sites depicted in blue
represent those sites that are embedded in a known or potential CTL epitope and circled site numbers are potentially affected by APOBEC
hypermutation. Sites marked with an asterisk occur in a region for which there is no available structure, therefore the positions are shown in
proximity to their actual locations.
doi:10.1371/journal.ppat.1000414.g002
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PLoS Pathogens | www.plospathogens.org 6 May 2009 | Volume 5 | Issue 5 | e1000414Figure 3. Selected sites that are embedded in potential CTL epitopes. The patient consensus sequence is at the top of each alignment, with
Fiebig stage, patient ID, and CON for consensus indicated. The proposed epitope is shown beneath the patient consensus, followed by the HLA.
Previously reported epitopes are provided in full, predicted epitopes are written with uppercase letters representing the anchor motif embedded in a
string of x’s. (A–E) are based on i) evidence for selection from the model implemented in HyPhy, ii) evidence of selection from locally concentrated
regional evidence for selection relative to extremely homogeneous early infection alignments, and iii) HLA appropriate known epitopes or anchor
motifs found using the Los Alamos HIV immunology database epitope location finder, ELF. (F) This potential escape mutation was found by the
phylogenetic test for changes enriched in later Fiebig stages, and was also supported by (ii) and (iii) above (Table 2). Mutations in (A–C) also were
favored in later Fiebig stages. (G) This set of mutations includes the only other sites in the entire data set of 81 subjects where mutations tended to
cluster over a small region in one person. No site in this region had statistical support for positive selection, but this cluster of mutations was
embedded in a potential epitope.
doi:10.1371/journal.ppat.1000414.g003
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PLoS Pathogens | www.plospathogens.org 8 May 2009 | Volume 5 | Issue 5 | e1000414sharing a mutation than can be explained by chance (nine patients
have a mutation at this codon, shared as seven at one codon
position and two at another; p=0.003).
We used a separate phylogenetic method to identify sites that
appear to have a different rate of mutation in the initial, compared
to later clinical stages of early infection (Table 2). This analysis was
based on the maximum likelihood tree including all the sequences
from the 81 homogeneous patients (an example of the substitution
pattern in one position is illustrated in Figure 4). Changes were
identified relative to the maximum likelihood estimate of the
transmitted virus in each individual. Mutations that tended to
occur more often in either later or earlier Fiebig stages were
indentified. Eight sites were mutated more frequently in later
Fiebig stages (III–VI), thus these were potentially selected by
immune pressure, while only one change recurred preferentially in
Fiebig I–II (in patient TT31P at position 454 in the alignment). In
this case, the subject had 67 sequences available, 49 carried an
Alanine in this position and 18 a Valine. Alanine, which is found
in the putative infecting virus, is very rare in the population at this
position, so the mutation is a candidate for early reversion to a
more fit form. In patient TT31P the mutation from Alanine to
Valine appears to have occurred more than once in independent
lineages, suggesting strong selection in this patient at this site in
early infection; however, this could also be explained by
transmission of two variants together with recombination prior
to, or soon after, transmission. The 8 sites highlighted using this
Figure 4. Maximum likelihood tree including all sequences from all 81 homogeneous patients illustrating the pattern of change in
one site. The tree is based on all nucleotide sequences and all positions in Env, and illustrates the mutational patterns in the context of the full tree
at amino acid position 83. Position 83 is highly conserved, and is His in most sequences in most subjects (indicated by the red Xs). In the 4 subjects
that are featured, it changes from His to Tyr in at least some of the sequences in each subject, indicated by the blue 0 s. Although the trees were
generated for each patient separately for the HyPhy analysis, this kind of repeated mutation pattern in a single site is an illustration of the kind of
change captured in the dN/dS ratio of the HyPhy analysis (Table 2). This site, 83, was also identified as interesting in the full tree analysis as it tended
to change from H to Y in patients at later Fiebig stages (Table 2).
doi:10.1371/journal.ppat.1000414.g004
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HyPhy method as well as one additional site that may be the
results of CTL escape as discussed above (Figure 3F).
We assessed by visual inspection whether there was evidence of
directional evolution in any of the 24 rapidly evolving sites
identified above (i.e. a consistent trend towards replacement of one
amino acid by another amino acid across multiple patients).
Position 646 (518 in HXB2), which occurs in the fusion peptide of
gp41, showed consistent replacement of Methionine with either
Valine or Isoleucine (the observed substitutions relative to the
within patient consensus are summarized for each selected site in
Table S1). This trend is remarkable when the data from all
patients is considered. Fewer than half (38 of 81) of the patients
had Methionine at this position in the inferred infecting viruses,
yet all nine of the patients with a nonsynonymous mutation at this
site had Methionine in the patient consensus sequence. The
probability of this occurring by chance is 0.001. Such strong
directional selection in early infection suggests the possibility of
reversion of amino acids associated with a selective transmission
bottleneck, but could also be explained by reversion of an escape
mutation associated with an immune response in the transmitting
virus. The apparent directionality could also be explained by a
sequence-specific mutational hotspot if the ATG codon, encoding
Methionine, results in a sequence motif that promotes mutation.
This is suggested by the fact that the mutation from M to V or I is
found in just a single sequence in each of the patients in which it
occurs and thus does not appear to show evidence of spreading in
the intra-patient viral population. However, none of the mutations
at this site are consistent with APOBEC3G/F mutation, and thus
rapid evolution at this site cannot be explained by known
mechanisms of hypermutation.
Since the number of potential N-linked glycosylation sites
(PNGSs) in env may affect the fitness of the virus by rendering it
more or less sensitive to neutralizing antibodies, we tested for
enrichment of mutations within PNGSs. The observed number of
mutations within PNGSs (NX[S|T]X where X is any amino acid
other than Proline) was not significantly different than the
expectation under a model of random mutation. We, therefore,
found no evidence of a tendency for mutations to disrupt PNGSs
in early infection. (p=0.736; Fisher’s exact test). We applied a
similar approach to determine whether there was an overall
enrichment of mutations within epitope-dense regions. In this case,
we compared the number of mutations that occur within epitope
rich regions (coordinates based on the best defined CTL/CD8+
epitope summary [25]) to the total number of mutations found
outside the epitope regions. There was no evidence of enrichment
of mutations occurring within a CTL epitope-dense region as
opposed to less dense regions (p=0.933, Fisher’s exact test).
However, because all mutations were considered in this case, the
lack of such evidence may result from the high level of noise in the
data (i.e. the fact that the majority of the observed mutations are
likely to be neutral or under purifying selection, rather than
positively selected). When we consider only the 24 rapidly evolving
sites, we find a weak trend (p=0.27) towards enrichment within
epitope rich regions (odds ratio: 1.6).
Analysis of insertions and deletions
For the homogeneous samples, the within-subject consensus is a
good approximation of the transmitted virus [15], and therefore
the direction of an insertion or deletion can be clearly ascertained.
Unique indels in these cases are one round of replication from a
viable virus, but they are most often frameshifting, and clearly
lethal, indicating they must have arisen in the newly infected host
and often are an evolutionary dead end. Most frameshifting indels
occurred only once within a patient, with the exception of single
base insertions and deletions that can occur in runs of like-bases,
most often in strings of A’s, although one hotspot is in a string of 6
T’s. It is difficult to resolve the relative frequency of such patterns
that result from in vivo mutations versus experimental artifacts
introduced during cDNA synthesis. Among the 81 homogeneous
infections, there were 31 observed single base insertions; 11 are
unique, and 20 were recurrent and distributed among a few
hotspots (Figure 5A). There were 53 single base deletions (1.7 fold
more common than insertions), 44 were unique, and 13 were
found in hotspots at runs of like-bases. All these indels were lethal
and frameshifting. In contrast, within the 21 heterogeneous
patients that carry indels that could have arisen in the donor,
there were 44 single base insertions, but 30 were compensatory
and resolved a nearby frameshift to keep the reading frame intact.
There were 32 single base deletions, and 17 were compensatory
mutations resolving a nearby frameshift. Hence, the single base
indels that were compensatory were found exclusively among the
heterogeneous cases, and thus were likely to represent viable
substitutions carried in through transmitted viruses. Unlike the
lethal single base indels, which were found distributed throughout
env but with a bias towards strings of like bases, the compensatory
single base indels were not proximal to like bases, were found
exclusively in heterogeneous infections, and were all concentrated
in the hypervariable V1, V2 and V4 loops (Figure 5A). This
suggests that single base indel mutations occur throughout env, but
are concentrated by selection in the hypervariable domains.
Multiple base indels showed even more remarkable contrasts
between homogeneous and heterogeneous infections. In the
homogeneous subjects, only 10 multiple base insertions were
found and all were unique events. Four, i.e. about a third, as would
be expected by chance, were in-frame and none compensated for
other frameshifts. Nine of the 10 were direct repeats of a nearby
stretch, although not always adjacent. In the following two
examples the region in bold is the region from the transmitted
strain that is repeated in the brackets:
TACTTGGAATA *GTACTTGGAATA*
[ GTACTTGGAATA ] ATACTGAAGGGTC
GGTAAC *GGT*[GGT ] AACGAGACC
In contrast, in heterogeneous infections there were 198
insertions, resulting from 49 unique patient/insertion combina-
tions (i.e. many of the insertions were observed in multiple
sequences from the same patient). Of the 49 unique insertions, 43
were in-frame, and the other six each had a nearby compensatory
mutation. There were many more multiple base deletions among
the homogeneous patients; 115 were found, again all unique, with
33 very large deletions (median 217 base pairs; range 40–601 base
pairs) that were presumably lethal. Of the 82 smaller deletions, 27
were in-frame (33%) and 55 were frameshifting. In contrast, in the
heterogeneous infections there were 289 deletions resulting from
82 unique patient/deletion combinations. Among these unique
deletions 56 were in-frame and 53 of these were in V1, V2 and V4.
Another 7 deletions were compensated by nearby indels. The in-
frame and out-of-frame multiple base indels were distributed very
differently across the genome (Figure 5B; Kolmogorov-Smirnov
p=0.00003). Out-of-frame indels were distributed throughout
Env but the short, presumably viable, in-frame ones were
concentrated in the hypervariable loops. This provides strong
evidence that indels do not occur as hotspots with a preference for
the hypervariable domains, but instead are preferentially main-
tained in the hypervariable regions, presumably because of
selective constraints that prevent length variation in other regions
HIV Evolution in Early Infection
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in these regions.
Discussion
The availability of data from a large number of individuals in
acute and early infection that harbor a homogeneous set of viruses
leads to an opportunity to study the pattern of diversification of
HIV-1 upon transmission to a new host. Because 78 of these
patients are believed to have been productively infected by single
viruses (three others are likely to have been infected by two closely
related viruses) the observed diversity can be inferred to have
arisen in the newly infected patient, and not in the individual from
whom the infection was acquired [15]. The size of the sample and
the quality of the sequence data provide the first opportunity to
assess whether there are consistent patterns of evolution that tend
to recur across multiple patients in early infection. Knowledge of
the infecting virus not only enables us to discriminate the direction
of the mutations but also allows us to distinguish between
insertions and deletions, which are likely to be a significant aspect
of HIV diversification in early infection. Differences in the lengths
of env variable loops between viruses in acute and chronic infection
have previously been reported in some subtypes [19,20,26] and
this may play a role in increased neutralization sensitivity of the
virus in acute infection. Such differences, if they exist, could result
from selective transmission of viruses with shorter variable loops,
or alternatively from selective events during acute infection.
We used HyPhy [18] to assess the selective pressure acting on
viruses in early infection. In our model we constrained v, the ratio
of nonsynonymous to synonymous substitution rates, to be the
same at a given site in the codon alignment across all patients. This
allowed us to identify sites that diversify rapidly on average. The
method we developed is sensitive to multiple independent
mutations at the same site in a given patient, or to the mutations
at the same site in multiple patients, or a combination of the two.
Because the sequence datasets from acute infection are very
homogeneous and generally well described by a star-like
phylogeny, it was rare to find multiple independent mutations
within the same patient and consequently we primarily identified
sites that tended to diversify rapidly in many patients. Many of the
sites we identified coincide with experimentally confirmed CTL
responses, indicating the importance of CTL escape early in
infection. However, the sites that we detected are likely to
represent only a fraction of the mutations that have been driven to
detectable frequency as a consequence of immune escape. For
example, because our method relies on shared patterns of
mutation across multiple patients we are unlikely to have power
to detect escape from immune responses mediated by rare HLA
alleles. Additionally, since parts of env, particularly in the variable
loops, were masked from the analysis due to ambiguous sequence
alignment, sites that confer resistance to neutralizing antibody
escape may have been overlooked. Although our results
underscore the importance of CTL escape in early infection they
do not provide a basis to discount the potential contribution of
escape from antibody responses to the evolution of env early in
HIV-1 infection.
Weused statistical model comparison to make the case that there is
evidence of adaptive evolution in HIV-1. To do thiswe compared the
Figure 5. Cumulative distribution of insertions and deletions in acutely infected patients. (A) The frameshifting single base indels
observed in early infection were distributed throughout the Env gene, with a few concentrated regions localized in particular strings of like bases (red
and black lines in the figure). As these substitutions are lethal, they must have arisen in the newly infected individual. In contrast, most of the single
base indels in the 21 heterogeneous infection cases were compensatory, associated with nearby mutations that resolved the reading frame, and most
of the compensated indels are localized in the hypervariable domains. (B) Similarly, multiple base frameshifting indels are distributed throughout Env,
while in-frame indels are concentrated in the hypervariable regions.
doi:10.1371/journal.ppat.1000414.g005
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allowed to evolve with v.1 to the fit of a model in which a subset of
sites were allowed to have v.1. The latter model had a significantly
better fit to the data for the sequences from Fiebig stages I–III and
Fiebig stages I–V, suggesting that the virus evolves adaptively in these
clinical stages. However, there are two important issues to consider
here. First, the fact that the positive selection model did not have a
significantly better fit to the data in Fiebig stages I–II does not prove
that viral diversification is not shaped by positive selection at thisstage
of infection. Sequences from stages I–II were highly homogeneous,
thus a very small number of mutations from the infecting virus were
observed in each patient, severely limiting the power to detect
evidence of selection. Secondly, a more general issue is that modelsof
codon evolution used to detect positive selection rely upon several
assumptions about the way the sequences are evolving and deviations
from these assumptions could lead to false positive results [27].
APOBEC induced mutations give rise to hotspots of amino acid
change which have a mutational rather than a selective cause.
Although we attempted to control for the effects of hypermutation by
removing sequences and patients with evidence of an elevated rate of
mutation in the APOBEC3 sequence context (Figure S1), the
enrichment of mutations in this context among sites placed in the
positive selection site class suggests that hypermutation may have had
an effect on the model comparison results.
The phylogenetic codon model we applied using HyPhy does not
account for recombination, which is known to cause false positive
inference of selection [28,29]. With the highly homogeneous intra-
patient datasets analyzed here, recombination is not likely to have a
large effect, because the sequences are, in most cases, well described
by a star phylogeny, with little internal structure in the tree.
However, in the case of the later Fiebig stage patients there is some
tree structure and recombination in these patients may have the
potential to cause false inference of positive selection. We therefore
tested all the homogeneous intra-patient sequence data sets for
evidenceofrecombinationusingGARD [30].Wefoundevidenceof
a single recombination breakpoint in the sequence alignments from
each of two patients (Z31 and MEMI). In both cases the breakpoint
is located near the end of the sequence alignment (just 3% and 10%
of the alignment lies to the right of the breakpoint for MEMI and
Z31, respectively) and therefore a single tree topology applies for
most of the alignment. Only in the case of MEMI do nucleotide
mutations occur to the right of the recombination breakpoint and at
inferred adaptively evolving sites (979, 981 and 989). Since these
mutations are also clustered and two of the three are confirmed
CTL escape mutations (Table 3), it appears unlikely that these sites
are false positives.
We tested for evidence of directional change in env in early
infection since this could impact our understanding of the nature
of the transmitted virus. It is clear from several studies
[15,20,26,31] that there is a severe viral population bottleneck
during HIV transmission, with newly transmitted infections
resulting frequently from transmission or outgrowth of a single
virion. If this extreme bottleneck is non-random and if viruses that
are best adapted for transmission from one host to the next tend to
be less well adapted for replication in the new host, then there may
be selection for reversion of the characteristics associated with
transmission in the newly infected host. If, further, these
characteristics are shared across multiple transmitted viruses, then
such reversions in early infection could potentially be observed
through our approach. We found evidence for purifying selection,
indicating the transmitted virus was a reasonably fit form prior to
the initial immune response imposing new selection constraints,
and we found relatively little support for characteristic patterns of
reversion at the population level in this cross-sectional view.
Discounting sites that may have been affected by APOBEC3G/
F hypermutation we found just a single site with significant
evidence for directional change. At position 646, (518 in HXB2),
which is in the fusion peptide of gp41, we found consistent
mutations from Methionine to Valine or Isoleucine. However, at
this site, there is just a single mutant sequence observable in each
of the nine patients in which the mutation is found, and this seems
inconsistent with a mutation that is coming under selection for
increased frequency in multiple patients. Furthermore, we do not
observe an increased frequency of Methionine in acute sequences
compared with chronic sequences at this site (data not shown), as
would be expected if the consistent mutations from Methionine to
Isoleucine or Valine represented reversion associated with selective
viral transmission. A single site was observed to undergo recurrent
change in a single subject in Fiebig stage II, and as this is prior to
the immune response it may be indicative of rapid reversion.
Alternatively, the observation could be explained instead by
transmission of two highly related forms, together with recombi-
nation either in the donor or soon after transmission.
Neutralizing antibody responses drive the evolution of viral
escape and are therefore thought to play an important role in
shaping the evolutionary changes observed in the envelope gene.
Mutations, insertions and deletions, as well as the distribution of
glycosylation sites along the envelope gene mediate the ability of the
virus to escape from neutralizing antibodies although the relative
contribution of each of these is unknown [32]. The role of N-linked
glycosylationsitesintheenvgeneinmaintainingthesurvivalofHIV-
1 during the earliest stages of infection is of particular interest as the
carbohydrate surface establishes the first means of contact between
the host and the virus. A previous study [32] compared the rate of
phenotypic escape of HIV-1 in recently infected individuals from
neutralizing antibodies to various characteristics of the envelope
gene and found that escape from neutralizing antibodies can occur
regardless of the variation in glycosylation or rate of insertions and
deletions in env. We did not find evidence of accelerated
diversification at potential N-linked glycosylation sites in early
infection, which suggests that if escape from neutralizing antibodies
is among the major driving forces of HIV-1 evolution at this stage
the mechanism is unlikely to be primarily through single base
substitutions in glycosylation sites, at least in the portion of env that
could be aligned with high confidence.
The majority of the rapidly evolving sites that recurred within
individuals were clustered and appeared to be under selection for
escape from cellular immune responses, and several of these
mutations are GRA substitutions in APOBEC3 motifs. We also
observed a highly significant enrichment overall for APOBEC3
motifs among the rapidly diversifying sites identified using HyPhy,
evenwhenstringentprecautionsweretakentoexcludethe15subjects
that had enrichment of GRA mutations withinthe APOBEC3 motif.
This suggests the possibility that APOBEC3 and imperfect Vif
function can play an important biological role in the patterns of
mutation found in early infection, and may contribute to determining
the first immune escape mutations. Thus base mutation rate may be
in some cases making a contribution to determining which immune
escape events happen first, along with fitness [33] and possibly T-cell
potency [34]. CTL immune responses have been shown to play a key
role in controlling viral replication in acute infection [35–38] and, in
animal models, positively selected CTL escape variants have been
reported within weeks of infection [39–41]. Escape from CTL
responses has been observed in humans both early and later in
infection [42,43] and escape from successive immune responses is an
important feature of HIV disease progression.
In our dataset several of the rapidly evolving sites are associated
withclustersofmutationsthatoccurincloseproximitytooneanother
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mutations at the same site. Given the short times since infection in
these patients and the otherwise highly homogeneous sequence
alignments, the multiplicity of alternative CTL escape pathways that
are already beginning to be explored by the virus in early infection is
remarkable. Several studies have also shown that upon transmission
some HIV-1 escape mutations can revert to the consensus in order to
re-establish effective replication efficiency within the new host [2,44–
46]. These reversion mutations frequently occur in structurally
c o n s e r v e dr e g i o n sa n do f t e nr e s i d ew i t h i nd e f i n e dC D 8e p i t o p e st h a t
are no longer subject to the restrictions of the original host’s HLAs
[2,44,45,47]. Envelope evolution towards the wild-type sequence
state after transmission is thought to occur in the absence of specific
CTL mediated immune pressure [34,48]. Even when the newly
infected host has the HLA allele associated with the response,
reversion can occur followed by development of a CTL response
targeting the wild-type epitope. Given that essentially all examples of
positive selection that also exhibited recurrent and localized
concentrated change in these 81 individuals occurred within one of
4 experimentally validated CTL epitopes, or in one of 2 putative
epitopes based on the individuals HLA, in this cross-sectional study
the earliest changes seemed to result more commonly from escape
rather than from reversion. However only in cases where CTL escape
was confirmed experimentally can we conclude with certainty that
the mutations are associated with escape.
In this study we have also shown that inactivating indels are
distributed evenly through env, with the exception of single base indels
in stretches of like-bases, which may in part be attributable to
experimental artifact. On the other hand, in-frame and compensated
indels are highly concentrated in 4 hypervariable domains in the
heterogeneous infections leading to extensive length variation in V1,
V2, V4 and V5. Because this was exclusively found in heterogeneous
infections, we assume the length variants most likely arose in the
newly infected individual’s partner, at a later phase of infection. This
indicates that there is no molecular trigger that increases the
background rate of indels in the hypervariable regions during reverse
transcriptions, and that the concentration of length variation in the
hypervariable domains is instead a consequence of selection. Also this
data does not provide evidence for selection for length variation
during acute infection, suggesting that this may occur during the
chronic phase of HIV-1 infection.
This cross-sectional study has provided a glimpse into the nature of
the diversification of HIV-1 following transmission in a population of
81 B clade infected individuals. As expected purifying selection acts
on single base mutations at the majority of sites as well as on indels,
butthereisalsoevidenceofasubsetofsitesthatdiversifymorerapidly
than expected under a model of neutral evolution. Our results suggest
that APOBEC3 may play a role in shaping the dynamics of early T-
cell immune escape. APOBEC3 motifs are highly enriched among
the rapidly diversifying sites. This could be the result of an
anomalously high mutation rate giving the appearance of selection
pressure when there is none, or a higher mutation rate promoting a
particular route of immune escape; the two are not mutually
exclusive. Finally early T-cell escape appears to be much more
common than reversion. We provide new evidence supporting the
idea that concentrated regions of change within an individual during
early infection [24] are frequently indicative of early escape from T-
cell responses.
Methods
Envelope sequences (n=3476) from 102 individuals infected with
HIV-1 subtype B, were generated using Single Genome Amplifi-
cation (SGA), as part of a previous study [15]. Among these
individuals, 81 were found to be likely to have been productively
infected byjusta single virion (orinfected cell),ortwoclosely related
viruses, while 21 were multiply infected since the level of diversity
seen in these cases was greater than could have accrued since the
time of infection. The 21 heterogeneous cases were not included in
the analysis of selection pressure, but were used for a comparison of
indel patterns. Intra-patient alignments were generated through an
iterative process, which included the alignment of all patient
consensus sequences, manual editing, and re-alignment of each
patients’ sequence data to the associated consensus, as described in
the supplementary data of Keele et al. [15]. Recombination analysis
was carried out with GARD [30] and evidence of recombination
was found in just two of the homogeneous patients. A further 14
from the heterogeneous group (analyzed previously [15]) showed
evidence of recombination that was confirmed by either GARD
[30] or Recco [49]. For our previous study, acutely infected patients
were staged using clinical criteria described by Fiebig et al. [17], into
six clinical stages from the earliest, Fiebig stage I, to the latest stage
of early infection, Fiebig stage VI. All regions of the alignment that
are translated in more than one frame, as well as all regions that
were ambiguously aligned, were masked for the analysis of selection
pressure. In addition, for model-based as well as the non-parametric
inference of selection, described later, individual sequences that
showed statistically significant evidence of APOBEC-mediated
hypermutation using Hypermut 2.0 (http://www.hiv.lanl.gov/
content/sequence/HYPERMUT/hypermut.html) were discarded.
Among the patients, 15 had a generalized increase in the rate of
GRA mutations in the context of the sequence motif associated
with APOBEC hypermutation. In these cases there was an excess of
GRA mutations in the APOBEC sequence context across all
sequences from the patients and not concentrated in individual
severely hypermutated sequences [15]. Since in these cases
APOBEC mediated mutations may be occurring at an elevated
rate, and this context-specific rate would deviate from the
evolutionary model, we carried out a separate analysis of selection
excluding these 15 patients. On the other hand, recurrent GRA
mutations in the context of APOBEC substitution motifs are
enrichedoverall in these data, suggesting APOBEC may have a role
in HIV-1 evolution in acute infection, thus we analyzed in parallel
the full set of 81 subjects. The alignments used for these analyses
were from our previous study [15] and are available at http://www.
hiv.lanl.gov/content/sequence/hiv/user_alignments/keele.
Model-based inference of selection in early infection
We used HyPhy [18] to assess the evidence for a subset of codon
sites in the env gene evolving under the influence of positive
Darwinian selection [50] in early infection. Essentially, this method
works by fitting standard codon models [51] of sequence evolution to
multiple sequence alignments from all of the patients. The critical
parameter of the codon models is v, the ratio of nonsynonymous to
synonymous substitution rates. If synonymous substitutions are
assumed to be generally neutral, then sites for which v is significantly
greater than one are inferred to be evolving under positive Darwinian
selection [52,53], although deviation from the evolutionary model as
aresultofenhancedmutationratesatspecificsites,forexample,those
embedded in APOBEC signature motifs, can also contribute in some
cases to an elevated v (see Discussion). We used the random effects
likelihood approach [54] and a model of site-to-site variation in v
equivalent to Model M2a from Wong et al. [55]. The selection
parameter, v, was modeled using a discrete distribution with three
classes: a purifying selection class for which v, constrained to be less
than one, is estimated from the data; a neutral class for which v=1
andapositiveselectionclassforwhichvis estimate from the data and
constrained to be greater than one. The fit of this model is compared
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Wong et al. [55], in which the proportion of sites in the positive
selection category is fixed at zero. Both of these are mixture models.
In the standard implementation of these models the likelihood of the
data is given by
LDh,T j ðÞ ~P
i
X
j
LD i vi~j,T,h j ðÞ p vi~j h j ðÞ
 !
where the product is taken over sites of the alignment, the sum is over
the discrete v classes and Di, T and h are the data at site i in the
alignment, the phylogenetic tree and the parameters of the model,
respectively. We extend this to data from multiple patients by writing
the likelihood as
P
i
X
j
P
k
LD i
k vi~j,Tk,h j
     
p vi~j h j ðÞ
  
whereDi
kand Tk are the data and tree from patient k,re sp e c t i v e l y .I n
this formulation v has the same value at a given site across all within-
patient sequence alignments. Following likelihood parameter estima-
tion, posterior probabilities of belonging to each of the site classes of v
were estimated for each site using the naı ¨ve empirical Bayes method
[56]. For all of the models, mutation rates were estimated separately
for each pair of nucleotides, thus assuming a general time-reversible
model of nucleotide substitution and the Goldman and Yang method
[57] was used to account for biased codon usage.
Maximum likelihood phylogeny-based comparison of
mutations in the earliest versus later clinical stages
To identify sites that showed different patterns of amino acid
change comparing samples from earlier versus later Fiebig stages,
we included the full dataset in a maximum likelihood tree based on
an alignment of all sequences from the 81 homogeneous patients.
We excluded extremely hypermutated sequences, but left in the 15
patients that showed overall enrichment for GRA mutations in an
APOBEC context. Phylogenetic trees used for this analysis were
inferred using PhyML [58], with a GTR nucleotide substitution
model and a gamma distribution for site-to-site rate variation [59].
We iteratively improved the model and the tree, using a GTR
model for base change with a likelihood estimate for the rate at each
site, which does not assume a particular distribution [60]. We then
identified amino acid changes from the transmitted virus that were
preferentially associated with either early or late Fiebig stages using
a modification of the contingency table approach as described
previously [59]. Maximum likelihood estimates of the most recent
common ancestor (MRCA), or founder virus, of each patient were
generated and these were used as a baseline to determine the
numberofwithinpatientchangesbetweentheMRCAandthetipat
each position in each patient. Substitutions are counted by taking
each taxon and following it back into the tree until an amino acid
change is observed, or until the ancestor hits the MRCA, whichever
comes first. For any taxon, there is an associated node in the tree for
the substitution, and tabulation is done in terms of unique identities
of these substitution nodes, so each change on an interior branch is
counted only once. The total number of changes was tallied across
all patients, and Fisher’s exact test was used to compare the number
of changes away from or towards each amino acid observed in
patients at later Fiebig stages against the number of the same
changes in patients at earlier Fiebig stages. All amino acid
comparisons were made at each site in the alignment, and various
comparisons between Fiebig stages were considered: Fiebig I versus
II–VI, I–II versus III–VI, I–III versus IV–VI, I–IV versus V–VI,
and I–V versus VI. The impact of multiple tests was addressed by
requiring a false discovery rate, or q-value, of ,0.2 [61].
Probability of finding repeated changes in a particular
position over the entire data set by chance
To calculate the probability of finding mutations repeatedly in
multiple patients at a given site in the absence of selection, we
assumed an exponential growth model with a large reproductive
ratio. In such a case, a small number of sequences sampled from a
patient are overwhelmingly likely to have a star phylogeny. Since
in a star phylogeny every mutation arises independently, the
probability of seeing a position mutated in at least one out of s
sequences sampled g generations from a common ancestor is
x~ 1{ 1{p ðÞ
sg ðÞ
  
, where p is the rate of mutation per
generation per position. The generation time (2 days [62]) and
mutation rate (2.16610
25 [63]), were the same as those used in
Keele et al. [15]. The probability of seeing this in at least n out of N
patients is y~
P N
i~n
N
i
  
xi 1{x ðÞ
N{i ðÞ . The probability of seeing
one such position in a sequence of length L is 1{ 1{y ðÞ
L
  
.
When the resulting probability is small, it can be approximated by
L N
n
  
sgp ðÞ
n. If the mutations are clustered in two sites in a
codon, instead of at one site, y needs to be replaced by 2y1y2
where y1 and y2 are the respective probabilities for the two sites
and the approximate resulting probability is L
N
n1
  
N
n2
  
sgp ðÞ
n,
when the n changes are split as n1 and n2 at the two sites. In the
calculations presented here, we used computer code to generalize
these results to the case when each patient had a different number
of sequences and generations since the last common ancestor.
Indel analysis
For this analysis, all insertions and deletions (indels) in each subject
relative to the subject consensus were systematically tracked, and
information regarding their location, length, and the precise inserted
or deleted fragments, and surrounded bases were retained and
analyzed. The data were divided into 4 sets, single base insertions and
deletions, and multiple base insertions and deletions, and each was
considered separately. For the sequences derived from the 81
homogeneous early infections, the direction of the indel could be
ascertained relative to the consensus, which was presumed to be the
t r a n s m i t t e ds t r a i n ,a n do b s e r v e di n d e l sw e r ea s s u m e dt ob er a n d o m
eventswithinthestudy subject. Thisassumptionwassupported by the
high frequency of frameshifting inactivating substitutions among
indels in the homogeneous infections. In contrast, the 21 heteroge-
neous infections had an excess of indels that were in-frame and thus
more likely to be viable, and so probably arose in the donor and were
transmitted independently to the recipient.
ELISpot assays
Ex-vivo IFN-c ELISpot assays. 18mer and 9mer peptides
were synthesized (MRC Human Immunology Unit, WIMM,
Oxford UK) to match sequences from patients MEMI, Z13, Z33
and Z36. Cryopreserved PBMC samples were thawed and rested
for 2 hours before being placed in the ELISpot plates at 16105
cells/well. Peptides in the peptide plates were mixed with 1:1 with
PBMC in the ELISpot plate to a final concentration of 2 mg/ml
and incubated for 20 hours at 37uC, 5% CO2. PBMCs and
peptides were tested in R-10 medium (10% fetal bovine serum,
86% RPMI 1640, 2 mM L-glutamine, 16penicillin-streptomycin
solution, 10 mM HEPES buffer and 1 mM sodium pyruvate (all
HIV Evolution in Early Infection
PLoS Pathogens | www.plospathogens.org 14 May 2009 | Volume 5 | Issue 5 | e1000414Sigma)). Coating, development and reading of ELISpot plates has
been described previously [64]. A definition of positive responses
was applied as: $50 SFU/ million, .46 background. For all
assays 6 negative control wells (media only) and 2 positive control
wells (10 mg/ml PHA (Sigma)) were used.
Cultured IFN-c ELISpot assays. This assay has been
previously described in Goonetilleke et al. [64]. In brief, short-
term cell lines (STCL) were set up whereby 26106 cell/ml of
PBMCs were stimulated with a pool of peptides specific to the
patient at 2 mg/ml in the presence of 25 ng/ml IL-7 (R&D
Systems). Cells were cultured at 37uC, 5% CO2 for 10 days in
RAB-10 (10% human AB serum, 86% RPMI 1640, 2 mM L-
glutamine, 16 penicillin-streptomycin solution, 10 mM HEPES
buffer and 1 mM sodium pyruvate (all Sigma)) and were
stimulated with 1800 U/ml IL-2 (Novartis) on days 3 and 7. On
day 10, the STCL were washed three times with PBS (Sigma) and
rested for 30 hours in RAB-10 at 37uC, 5% CO2. On day 11,
46104 cells/well were placed into an IFN-c ELISpot as described
above and stimulated by each individual peptide in triplicate at
2 mg/ml in the presence of RAB-10.
HLA typing. HLA typing was performed by T. Rostron
(WIMM, Oxford UK) using the Sequence-Specific Primer (SSP)
method adapted from Bunce et al. [65], that uses allele-specific
primer combination in PCR amplification to provide absolute HLA
resolution to 2-digits and high probability resolution to 4-digits.
Intracellular cytokine assay
Cryopreserved peripheral blood mononuclear cells were thawed,
rested overnight and stimulated for 6 hours at 37uC, 5% CO2 with
2 mg/ml of individual HIV-1 peptides representing the wild-type and
escape sequences of the epitopic regions. The stimulation was
conducted in presence of anti-CD28 mAb (1 mg/ml; L293; BD
Biosciences), anti-CD49d mAb (1 mg/ml; L25; BD Biosciences),
anti-CD107a-Alexa 680 (H4A3; BD Biosciences), 5 mg/ml Brefeldin
A (Sigma) and 1 mg/ml Golgi Stop (Pharmingen). After stimulation,
the PBMCs were stained with LIVE/DEAD Fixable Violet Dead
Cell Stain (InVitrogen, Eugene, OR), anti-CD14-Cascade Blue
(M5E2), anti-CD19-Cascade Blue (HIB 19) (to exclude non-viable
cells), anti-CD4-Cy5.5-phycoerythrin (PE) (M-T477), anti-CD8-
QD705 (RPA-T8), anti-CD27-Cy5-PE (M-T271), anti-CD57-
QD605) (NK-1), anti-CD45RO-PE-Texas Red (all clones were BD
Biosciences, but CD45RO BeckmanCoulter) for 20 minutes at room
temperature. PBMC were then fixed and permeabilized with
Cytofix/Cytoperm (Pharmingen). PBMC were stained with anti-
CD3-Cy7-APC (SK7), anti-IFN-g-fluorescein isothiocyanate (FITC)
(B27),anti-IL-2-Allophycocyanin(APC)(MQ1-17H12),anti-TNF-a-
Cy7-PE (MAb11) and anti-MIP-1b-PE (D21-1351) (all BD Biosci-
ences) for 45 min at 4uC. After washing and fixation samples were
run on a custom built LSRII (BD Biosciences). A minimum of
300,000 total events was acquired using a custom made LSR II flow
cytometer (BD Bioscience, San Jose, CA). Data analysis was
performed using FlowJo 8.8.2 software (TreeStar), Pestle for
background subtraction, and Spice for frequency analysis. (Pestle
and Spice provided by Dr. M. Roederer Vaccine Research Center,
NIH, Bethesda).
‘Memory’ CD8 T-cells are defined as live / lymphocytes / CD3
/ CD8 / excluding the CD27hiCD45RO-negative population.
Individual and total cytokine responses were considered as positive
if the frequency of the total responding memory CD8+ subset was
greater than 0.05% after background subtraction.
Supporting Information
Figure S1 Highlighter plots (http://www.hiv.lanl.gov/content/
sequence/HIGHLIGHT/highlighter.html) illustrating different
patterns of hypermutation. Green stars show mutations consistent
with Apobec hypermutation. Statistical tests of hypermutation
were performed using Hypermut (http://www.hiv.lanl.gov/content/
sequence/HYPERMUT/hypermut.html). (A) Sequences from a
patient showing no evidence of hypermutation. (B) A patient with a
singlesignificantlyhypermutated sequence (P=0.003). (C) Sequences
from a patient showing an overallelevated rate of hypermutation. No
single sequence showed significant evidence of hypermutation;
however, after compressing the mutations into a single sequence
(using a tool available from the highlighter website) and re-running
Hypermut with the compressed sequence, there was a significant
elevation in the rate of GRA mutations in the Apobec sequence
context (P=9610
26).
Found at: doi:10.1371/journal.ppat.1000414.s001 (1.46 MB TIF)
Table S1 Observerd mutations, sequence context within specific
patients, and possible alternative explanations besides selection.
Found at: doi:10.1371/journal.ppat.1000414.s002 (0.09 MB XLS)
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